Anika Therapeutics Inc (ANIK)

49.64
NASDAQ : Health Care
Prev Close 48.14
Day Low/High 47.36 / 49.70
52 Wk Low/High 35.07 / 54.96
Avg Volume 106.10K
Exchange NASDAQ
Shares Outstanding 14.62M
Market Cap 703.96M
EPS 2.10
P/E Ratio 20.66
Div & Yield N.A. (N.A)

Latest News

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

Jim Cramer likes SWHC and BX, but not NAT and DBD.

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Cramer previews important earnings reports scheduled for the coming week.

Anika Reports Third Quarter 2016 Financial Results

Anika Reports Third Quarter 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics (ANIK) Shares Cross Below 200 DMA

Anika Therapeutics (ANIK) Shares Cross Below 200 DMA

In trading on Thursday, shares of Anika Therapeutics Inc. crossed below their 200 day moving average of $45.73, changing hands as low as $45.26 per share.

Anika To Issue Third-Quarter 2016 Financial Results And Business Highlights On Wednesday, October 26

Anika To Issue Third-Quarter 2016 Financial Results And Business Highlights On Wednesday, October 26

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2016 financial results after the close of the market on Wednesday, October 26, 2016 and to hold a conference...

Anika Announces Data Presentations On HYALOFAST Hyaluronic Acid-Based Scaffold At 2016 World Congress Of The International Cartilage Repair Society

Anika Announces Data Presentations On HYALOFAST Hyaluronic Acid-Based Scaffold At 2016 World Congress Of The International Cartilage Repair Society

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced four data presentations...

Anika To Participate In Upcoming Investor Conferences

Anika To Participate In Upcoming Investor Conferences

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its Chief Financial...

Anika Reports Second Quarter 2016 Financial Results

Anika Reports Second Quarter 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika To Issue Second-Quarter 2016 Financial Results And Business Highlights On Wednesday, July 27

Anika To Issue Second-Quarter 2016 Financial Results And Business Highlights On Wednesday, July 27

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2016 financial results after the close of the market on Wednesday, July 27, 2016 and to hold a conference call...

Anika Therapeutics Stock Sees Short Interest Decline 25.2%

Anika Therapeutics Stock Sees Short Interest Decline 25.2%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 392,173 share decrease in total short interest for Anika Therapeutics Inc. , to 1,165,714, a decrease of 25.17% since 06/15/2016.

Here's Whats Next for Anika Therapeutics Post-Breakout

Here's Whats Next for Anika Therapeutics Post-Breakout

The charts are showing a long-term price target of $76.

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's New Lifetime High Stock

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's New Lifetime High Stock

Trade-Ideas LLC identified Anika Therapeutics (ANIK) as a new lifetime high candidate

Anika To Present At The Singular Research 11th Annual Spring Select Conference On June 9, 2016

Anika To Present At The Singular Research 11th Annual Spring Select Conference On June 9, 2016

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Announces European Commercial Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis

Anika Announces European Commercial Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the commercial launch...

3 Small Biotechs That Look Very Healthy

Peter Lynch and other market legends would love these names.

Anika Therapeutics Announces Canadian Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics Announces Canadian Launch Of CINGAL For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the commercial launch...

Anika Reports First Quarter 2016 Financial Results

Anika Reports First Quarter 2016 Financial Results

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics To Issue First-Quarter 2016 Financial Results And Business Highlights On Wednesday, April 27

Anika Therapeutics To Issue First-Quarter 2016 Financial Results And Business Highlights On Wednesday, April 27

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its first-quarter 2016 financial results after the close of the market on Wednesday, April 27, 2016 and to hold a conference call...

Anika Appoints New Chief Medical Officer And Chief Operations Officer

Anika Appoints New Chief Medical Officer And Chief Operations Officer

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced the executive...

Anika Therapeutics Wins CE Mark Approval For Cingal® For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics Wins CE Mark Approval For Cingal® For The Treatment Of Pain Associated With Osteoarthritis Of The Knee

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid "HA" technology, today announced that it received CE Mark...

Commit To Purchase Anika Therapeutics At $40, Earn 13.1% Annualized Using Options

Commit To Purchase Anika Therapeutics At $40, Earn 13.1% Annualized Using Options

Investors eyeing a purchase of Anika Therapeutics Inc. stock, but cautious about paying the going market price of $44.09/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Anika Therapeutics Announces $25 Million Accelerated Share Repurchase

Anika Therapeutics Announces $25 Million Accelerated Share Repurchase

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced that it will enter into an...

Anika Therapeutics Delivers Strong Performance With Record Product Revenue For The Fourth Quarter And Full Year 2015

Anika Therapeutics Delivers Strong Performance With Record Product Revenue For The Fourth Quarter And Full Year 2015

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today reported financial results for the...

Anika Therapeutics To Present At The 2016 Canaccord Genuity Musculoskeletal Conference On March 1

Anika Therapeutics To Present At The 2016 Canaccord Genuity Musculoskeletal Conference On March 1

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that its President and...

Anika Therapeutics To Issue Fourth-Quarter 2015 Financial Results And Business Highlights On Wednesday, February 24

Anika Therapeutics To Issue Fourth-Quarter 2015 Financial Results And Business Highlights On Wednesday, February 24

Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that the Company plans to issue its fourth-quarter 2015 financial results after the close of the market on Wednesday, February 24, 2016 and to hold a conference...

Anika Therapeutics, Inc. Announces First Patient Enrolled In FastTRACK Phase III HYALOFAST® Study

Anika Therapeutics, Inc. Announces First Patient Enrolled In FastTRACK Phase III HYALOFAST® Study

Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced the enrollment of the first...

Commit To Purchase Anika Therapeutics At $35, Earn 13.7% Annualized Using Options

Commit To Purchase Anika Therapeutics At $35, Earn 13.7% Annualized Using Options

Investors eyeing a purchase of Anika Therapeutics Inc. shares, but tentative about paying the going market price of $38.55/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's Weak On High Relative Volume Stock

Trade-Ideas: Anika Therapeutics (ANIK) Is Today's Weak On High Relative Volume Stock

Trade-Ideas LLC identified Anika Therapeutics (ANIK) as a weak on high relative volume candidate